A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Melanoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. All patients must be either Stage IIIb/c/d or Stage IV melanoma according to the American Joint Committee on Cancer (AJCC) (8th edition) and have histologically-confirmed melanoma that is felt to be surgically unresectable in order to be eligible.
    2. Tumor tissue from the resected site of disease must be provided for biomarker analyses. In order to be treated, a patient must have tissue available for PD-L1 expression analysis by IHC and other assays obtained within 6 months of starting treatment.
    3. Prior treated CNS metastases must be without MRI evidence of recurrence for at least 4 weeks after treatment. <\ol>

You may not be eligible for this study if the following are true:

    1. Patients with carcinomatosis meningitis or a history of current ocular/uveal melanoma are excluded.
    2. Patients with previous nonmelanoma malignancies are excluded unless a complete resection or remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period (exceptions include, but are not limited to, nonmelanoma skin cancers, in situ bladder cancer, in situ gastric cancer or gastrointestinal stromal tumor, in situ colon cancers, in situ cervical cancers/dysplasia, or breast carcinoma in situ).
    3. Patients with active, known, or suspected autoimmune disease. <\ol>


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.